Cidara Therapeutics (CDTX) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adenosine, adware, allegedly, anticancer, Antimicrobial, AstraZeneca, attenuate, authentication, autoimmune, brexafungerp, chemotherapy, CMO, composition, conventional, Curve, decade, dedicated, deepen, degradation, destroy, diligence, disagreement, discretionary, durable, email, expressed, flooding, fosmanogepix, gather, hardware, harvesting, honor, immunosuppressive, infer, inhibitor, injection, inquiry, introduce, lawfully, mAb, microenvironment, misconduct, necessitate, oleclumab, Oric, outlining, pathway, PCR, pharmacokinetic, PLC, presidential, quemliclustat, receivership, recession, relocate, replication, retaliatory, REZZAYO, REZZAYOTM, runway, sample, SD, secondary, server, Signature, Silicon, slowdown, stromal, subset, suppressor, tract, undermine, unsettled, Valley, wiretapping, WuXi, XDC

Removed: absent, account, accuracy, actively, adjusted, allocable, arm, ASU, attest, attorney, bearing, biometric, brand, breakdown, burdensome, censure, collection, committed, confirm, contact, cure, deductible, deficiency, delete, deployment, detail, detailed, documentation, embedded, emerge, enabled, enact, enacting, endeavor, engineering, existed, exploitable, extra, fashion, feature, filer, founded, goodwill, historical, informally, instrument, intentional, lab, landscape, leakage, long, malfunction, mandating, mark, marketplace, milligram, misdirected, misstatement, mobile, monitored, noted, oncological, opt, organizing, PK, posture, precision, preferable, processor, proper, propose, randomization, reconsider, reexamining, registered, regular, reliability, reliable, remediated, remediation, removing, residency, resistance, retrospective, rezfungin, ruling, separation, sharing, showed, social, staffing, subjective, Switzerland, turnover, uncollectable, Undetected, unreliable, utilizing, vital, waiver, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CDTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.1

SEVENTH AMENDMENT TO LEASE DATED APRIL 20, 2023

Nancy Ridge Technology Center, L.P., a California limited partnership (“Lessor”), and Cidara Therapeutics, Inc., a Delaware corporation, (“Lessee”), hereby amend the Lease dated June 9, 2014 (as previously amended, the “Lease”), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 (“Premises”) as follows:

1)Expiration Date: The Lease Term is hereby extended and the Expiration Date shall be December 31, 2026.

2)Increase in Base Rent: On January 1, 2024 the Base Rent shall increase to $133,371 per month. On January 1, 2025, and every twelve (12) months thereafter, the Base Rent shall increase four percent (4%).

3)Renewal Options: The two two-year options to renew the Lease described in paragraph #57 of the Addendum to Lease have not been exercised, and remain in effect and available to Lessee.

4)Confidentiality: The terms of the Lease are confidential. No party to the Lease shall disclose any of the terms of the Lease to any other party, provided that Lessee may disclose such terms to Lessee's employees, directors, officers, agents and proposed transferees.

5)No Default: To each party's knowledge, neither party is currently in Default or Breach of any of the terms or conditions of the Lease.

6)Authority to Execute: Each person executing this Amendment represents and warrants to all parties that he or she is duly authorized to execute and deliver this Amendment on behalf of that party.

All other terms and conditions of the Lease shall remain in full force and effect. All capitalized terms used herein but not defined herein shall have the meanings ascribed thereto in the Lease.

Lessor: Nancy Ridge Technology Center, L.P., a California Limited Partnership

By: Nancy Ridge Technology Center, LLC, a California Limited Liability Company, its General Partner

By: /s/ Chris Loughridge Chris Loughridge, its Manager

Lessee: Cidara Therapeutics, Inc., a Delaware corporation By: /s/ Shane Ward

Printed: Shane Ward

Title: Chief Operating Officer